机构名称：
¥ 1.0
TITLE: PSYCHOTROPIC MEDICATIONS 5.16 Authority: Chapter 69.41 RCW Legend Drugs - Prescription Drugs Title 71A RCW Developmental Disabilities Chapter 246-888 WAC Medication Assistance Chapter 388-101 WAC Certified Community Residential Services and Supports Chapter 388-101D WAC Requirements for Providers of Residential Services and Supports Chapter 388-825 WAC Developmental Disabilities Services Reference: DDA Policy 5.06 Client Rights DDA Policy 5.14 Positive Behavior Support Principles DDA Policy 5.15 Restrictive Procedures: Community DDA Policy 5.21 Functional Assessments and Positive Behavior Support Plans DDA Policy 5.22 Restrictive Procedures: Residential Habilitation Center DDA Policy 6.19 Residential Medication Management BACKGROUND Clients have the right to a dignified existence, to self-determine, and communicate or associate with people of their choosing.为了从这些权利中受益，客户有权获得医疗保健评估和护理计划，参与和直接医疗服务的权利。客户有权以最少的侵入性，限制性方法对待，并由客户确定的和记录的身体和行为健康状况症状所指示。客户有权没有不必要的药物和化学限制来治疗客户的身体和行为健康症状。DDA政策5.06，客户权利和WAC 388-823-1095对客户可能行使的权利提供了更深入的了解。发展障碍管理（DDA）打算以最少的限制性和最不动力的方式为残疾人提供服务和支持。因此，精神药物不一定是行为健康问题首选的第一个或唯一治疗方法。积极行为支持可能同样有效。
DDA策略
主要关键词
相关文件推荐
